Abstracts tagged "hydroxychloroquine and quality improvement"

Abstract Number: 323 • 2019 ACR/ARP Annual Meeting
Compliance with Hydroxychloroquine Dosage According to 2016 American Academy of Ophthalmology (AAO) Guidelines: A Study with 6591 Patients
Thein Swe¹ and Andras Perl ¹, ¹SUNY Upstate Medical University, Syracuse, NY
Background/Purpose: Hydroxychloroquine (HCQ) induced retinal toxicity remains a major concern because it can lead to irreversible damage to retinal pigment epithelium and blindness. American Academy…
Abstract Number: 1243 • 2018 ACR/ARHP Annual Meeting
A Quality Improvement Initiative to Increase Adherence to Hydroxychloroquine Dosing Guidelines at an Academic Medical Center
Ryan Jessee, Stephanie L. Giattino, Atul Kapila, Katherine Kaufman, Jon Golenbiewski, Brian J. Andonian, David Leverenz and Lisa Criscione-Schreiber, Department of Medicine, Division of Rheumatology and Immunology, Duke University, Durham, NC
Background/Purpose: In 2016, the American Academy of Ophthalmology published revised guidelines on HCQ dosing, recommending a maximum daily dose of 5mg/kg actual body weight as…
Abstract Number: 1244 • 2018 ACR/ARHP Annual Meeting
Hydroxychloroquine Quality Improvement Project at UF Health Jacksonville Rheumatology Clinics
Shameik Brooks, Gurjit Kaeley and Lanh Dang, UF Health Jacksonville, Jacksonville, FL
Background/Purpose: Hydroxychloroquine (HCQ) is a treatment option for lupus erythematosus and rheumatoid arthritis. The risk of retinopathy in the first 5 years of therapy is…
Abstract Number: 2034 • 2017 ACR/ARHP Annual Meeting
New Guidelines on Hydroxychloroquine Dosage – Where Are We?
Shriyanka Jain¹ and John Waterman², ¹Division of Rheumatology, University of Connecticut, School of Medicine, Farmington, CT, ²Rheumatology, Connecticut VA Healthcare System, Newington, CT
Background/Purpose: Hydroxychloroquine (HCQ) is a widely-used medication in many rheumatologic conditions. The most worrisome toxicity is irreversible damage to retinal pigment epithelium which can lead…
Abstract Number: 1032 • 2015 ACR/ARHP Annual Meeting
Adherence Patterns to American Academy of Ophthalmology Guidelines for Hydroxychloroquine Baseline Screening: Quality Assurance Assessment Utilizing Highmark Claims Data
Christina Payne¹, Patricia Gladowski², James Byers Jr.², Amy Tang³ and Mary Chester M. Wasko⁴, ¹Allegheny General Hospital Department of Medicine, Allegheny Health Network, Pittsburgh, PA, ²Enterprise Knowledge Discovery, Highmark Health, Pittsburgh, PA, ³Asthma, Allergy and Autoimmunity Institute, Allegheny Health Network, Pittsburgh, PA, ⁴Lupus Center, Pittsburgh, PA
Background/Purpose: Hydroxychloroquine (HCQ) is an antimalarial agent used commonly to treat selected autoimmune rheumatic diseases because of its therapeutic benefits, low cost, and favorable safety…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].